Advanced search×

Rebuttal: palivizumab for the prevention of respiratory syncytial virus infection.

Kelly A Smart, Krista L Lanctôt, and Bosco A Paes

Can Fam Physician 56(10):988-91 (2010) PMID 20944037

Version: za2963e q8za0 q8zb9 q8zcc q8zd0 q8ze2 q8zfc q8zg4
View PDF

Similar articles you may find interesting…

  1. When risk communication backfires: Randomized controlled trial on self-affirmation and reactance to personalized risk feedback in high-risk ...
    Natalie Schüz, Benjamin Schüz, and Michael Eid

    Health Psychol 32(5):561-70 (2013) PMID 23646839

    A multivariate analysis of variance (MANOVA) revealed a three-way interaction between risk feedback, the self-affirmation manipulation, and risk status for the three outcome measures. Follow-up analyses of variance (ANOVAs) indicated that high-risk individuals receiving only the risk feedback interv...
  2. Genetic stability of RSV-F expression and the restricted growth phenotype of a live attenuated PIV3 vectored RSV vaccine candidate (MEDI-534...
    Christine L Nelson, Roderick S Tang, and Elizabeth A Stillman

    Vaccine (2013) PMID 23623857

    MEDI-534 is the first live, attenuated and vectored respiratory syncytial virus (RSV) vaccine to be evaluated in seronegative children. It consists of a bovine/human parainfluenza virus type 3 (PIV3) backbone with the RSV fusion glycoprotein (RSV-F) expressed from the second position...
  3. EPIRETINAL MEMBRANE RECURRENCE: Incidence, Characteristics, Evolution, and Preventive and Risk Factors.
    Otman Sandali, Mohamed El Sanharawi, and Claire Monin

    Retina (2013) PMID 23612050

    : The incidence of ERM recurrence was 5% (22/440), and 2% of the patients were reoperated (9/440). Epiretinal membrane recurrence was symptomatic in 9 cases (41%) and asymptomatic in 13 cases (59%). ILM peeling was the only factor preventing ERM recurrence (adjusted odds ratio = 0.33, P = 0.026). The...